Verastem opened lower at $8.84, compared with its previous close of $9.09. In the last trading session, the stock traded between $8.41 and $9.12. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Verastem is now worth
$ 24.04
Resulting in a loss of
$ 75.96 (75.96%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.64 (-7.03%)
Day High
$9.12
Day Low
$8.41
Day Open
$8.84
Prev Close
$9.09
Volume
16,70,412
1W Return
-14.29%
1M Return
2.25%
3M Return
19.63%
6M Return
73.18%
1Y Return
0.01%
Fundamentals
Market Cap ($ Mn)
1,065
PE Ratio
-
PB Ratio
13.07
PEG Ratio
-
ROE
-6,385.92%
ROCE
-175.87%
EPS (TTM)
$-0.79
Investment Returns
1 Week
-14.29%
1 Month
2.25%
3 Months
19.63%
6 Months
73.18%
9 Months
33.30%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
2.1
Jun 25
11.2
Sep 25
17.5
Dec 25
40.1
Jun 26
24.0
Sep 26
Updates
7Nov
RBC Capital lowers Verastem price target to $18, keeps Outperform
RBC Capital lowered Verastem's price target from $19 to $18. Analyst Leonid Timashev maintained an Outperform rating. The target reduction represents a $1 decrease.
6 days ago
6Nov
HC Wainwright raises Verastem price target to $20, maintains buy
HC Wainwright maintains a Buy rating on Verastem. Price target raised from $18 to $20 by analyst Andres Y. Maldonado.
6 days ago
6Nov
Verastem Oncology Q3 revenue up 114% to $24 million amid CEO transition
Net product revenue reached $24.0 million in Q3 2026, up 114% YoY. Non-GAAP adjusted net loss widened to $72.8 million from $39.1 million. Company raised $250 million, bringing pro forma cash to $422.8 million. Michael Bailey named incoming CEO, succeeding Daniel Calkins. VS7375 showed 50% ORR in second-line pancreatic cancer patients.
7 days ago
16Oct
Mizuho raises Verastem price target to $14, maintains outperform
Mizuho raised Verastem's price target from $13 to $14. The analyst maintained an Outperform rating on the stock. Graig Suvannavejh is the analyst responsible for the revision.
27 days ago
14Oct
Verastem Oncology reports 41% ORR for VS-7375 in pancreatic cancer
VS-7375 achieved 41% confirmed ORR in 2L+ pancreatic cancer and 43% in NSCLC. Disease control rate in pancreatic cancer reached 86%, with 80% overall survival. Company aligned with FDA on Phase 3 trial design for first-line metastatic PDAC. Raised $250 million through share offering to support clinical development. Michael Bailey appointed president and CEO effective January 1, 2027.
29 days ago
14Oct
Verastem Oncology prices $247.5M offering for cancer drug development
Verastem Oncology raised $247.5 million in gross proceeds via an underwritten offering. Common stock priced at $8.00 per share for 30.94 million shares. Proceeds allocated to VS-7375 program development and working capital.
